Having validated the performance of its mass spec-based TIQUAS system for the identification of protein biomarkers in clinical samples, proteomics firm Activiomics is now aiming to step up its biomarker development efforts.

The firm is looking to both add to its internal biomarker pipeline, which is currently focused primarily on breast cancer, and to expand its service business to include collaborative companion diagnostic research, CEO Kevin FitzGerald told ProteoMonitor.